Lot A. Devriese - Concepedia

Author

Lot A. Devriese

Also Known As

Devriese, L., L A Devriese, L Devriese, L. A. Devriese, L. DeVriese, L. Devriese, L.A. Devriese, Lot A. Devriese, Lot A Devriese, Lot A. Devriese

140

Publications

3.2K

Citations

H-Index

Concepts

All Affiliations

University Medical Center Utrecht Utrecht University The Netherlands Cancer Institute Oncode Institute Maastricht University

About

Lot A. Devriese is an author at University Medical Center Utrecht specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	17	886
2	Health Sciences	5	5	138
3	Engineering	2	2	92
4	Gastroenterology	1	1	25
5	Hepatology	1	1	43

Lot A. Devriese

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Oral Mucosal Organoids as a Potential Platform for Personalized Cancer Therapy Else Driehuis, Sigrid Kolders, Sacha Spelier, Cancer Discovery	2019	399
Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial Suzanne L. Topalian, Shailender Bhatia, Asim Amin, Journal of Clinical Oncology	2020	265
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs Daphne van der Velden, Louisa R. Hoes, Hanneke van der Wijngaart, Nature Drug RepositioningOncologyPreclinical Drug EvaluationDrug RepurposingPharmacology	2019	252
Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial Robert L. Ferris, William C. Spanos, Rom S. Leidner, Journal for ImmunoTherapy of Cancer	2021	205
Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC) Emma J. de Ruiter, Frans J. Mulder, Bregje M Koomen, Modern Pathology Tumor BiologyPd-l1 Immunohistochemical AssaysCancer ImmunosurveillanceNeoadjuvant TherapyMedicine	2020	138
Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: Results from CheckMate 358 R. Wendel Naumann, Ana Oaknin, Tim Meyer, Annals of Oncology Checkmate 358Cervical CancerMedicineCancer ManagementGynecology	2019	89
Patient-derived head and neck cancer organoids allow treatment stratification and serve as a tool for biomarker validation and identification Rosemary Millen, W. W. B. de Kort, Mandy Koomen, Med	2023	89
Circulating tumor cell detection in advanced non-small cell lung cancer patients by multi-marker QPCR analysis Lot A. Devriese, AJ Bosma, M.M. van de Heuvel, Lung Cancer OncologyEngineeringMulti-marker Qpcr AnalysisCancer DetectionMedicine	2011	53
A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer Timothy J. Molloy, Lot A. Devriese, Helgi H. Helgason, British Journal of Cancer	2011	51
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial Ana Oaknin, Kathleen N. Moore, Tim Meyer, The Lancet Oncology Checkmate 358Metastatic Cervical CancerCervical CancerMedicineClinical Trials	2024	48

Page 1